Netherlands· NL-2de96fbf5acf
Imdylltra 10 mg poeder voor concentraat en oplossing voor oplossing voor infusie
A tarlatamab product containing tarlatamab, registered in Netherlands by Amgen Europe B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Tarlatamab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX33 (tarlatamab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Tarlatamab · ATC L01FX33
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TARLATAMAB
- Manufacturer
- Amgen Europe B.V.
- Country
- Netherlands (NL)
- ATC code
- L01FX33
- ATC class
- Tarlatamab
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/26/2033
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tarlatamab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenIMDYLLTRA 1 mg Pulver till koncentrat och lösning till infusionsvätska, lösningAmgen Europe B.V.
- CanadaIMDELLTRAAMGEN CANADA INC
- SwitzerlandImdylltra 1 mg, Pulver für ein Konzentrat und Stabilisatorlösung zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaIMDYLLTRAAmgen Europe B.V., Breda
- SpainIMDYLLTRA 1 MG POLVO PARA CONCENTRADO Y SOLUCIÓN PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandImdylltraAmgen Europe B.V.
- FranceIMDYLLTRA 1 mg, poudre pour solution à diluer et solution pour solution pour perfusionAMGEN EUROPE
- United KingdomImdylltra 10mg powder for concentrate and solution for solution for infusion vialsAmgen Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Imdylltra
- Norway · Imdylltra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c4c3842b-334b-4d2b-8508-6593dc6d86c3 GET /v1/drugs/c4c3842b-334b-4d2b-8508-6593dc6d86c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/imdylltra-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Tarlatamab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp135483",
"excipients": [
"CITROENZUUR 1-WATER (E 330)",
"GLUTAMINEZUUR (L-) (+) (E 620)",
"LYSINEHYDROCHLORIDE, L-",
"NATRIUMHYDROXIDE (E 524)",
"NATRIUMHYDROXIDE (E 524)",
"POLYSORBAAT 80 (E 433)",
"POLYSORBAAT 80 (E 433)",
"SACCHAROSE",
"STIKSTOF (HEAD SPACE) (E 941)",
"WATER VOOR INJECTIE"
],
"substances": [
"TARLATAMAB"
],
"leaflet_url": null,
"authorised_at": "2026/05/29",
"procedure_number": "EMEA/H/C/006451",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/26/2033",
"additional_monitoring": "N"
}See everything about tarlatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.